| Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that icosapent ethyl be reimbursed to reduce the risk of CV events (CV death, non-fatal myocardial infarction [MI], non-fatal stroke, coronary revascularization, or hospitalization for unstable angina) statin-treated patients with elevated triglycerides (TGs), if the following conditions are met: Conditions for reimbursement : Initiation criteria 1. Patients aged 45 years or older with established cardiovascular disease (CVD) (secondary prevention population). 2. Patients must have a fasting TG of 1.7 mmol/L or greater and lower than 5.6 mmol/L at baseline, measured within the preceding three months before starting treatment with icosapent ethyl. 3. Patients must have a low-density lipoprotein cholesterol (LDL-c) greater than 1.0 mmol/L and lower than 2.6 mmol/L at baseline and be receiving a maximally tolerated statin dose, targeted to achieve an LDL-c lower than 2 mmol/L, for a minimum of four weeks. Prescribing conditions : Icosapent ethyl should be prescribed in conjunction with a statin. Pricing conditions : A reduction in price
|
|---|